Inflarx NV logo

IFRX - Inflarx NV News Story

$3.68 -0.0  -0.5%

Last Trade - 5:40pm

Sector
Healthcare
Size
Small Cap
Market Cap £116.0m
Enterprise Value £46.1m
Revenue £n/a
Position in Universe 4732nd / 6851

BRIEF-InflaRx Announces Start Of Phase III Part Of Phase II/III Clinical Trial With IFX-1 In COVID-19-Induced Pneumonia

Mon 14th September, 2020 12:42pm
Sept 14 (Reuters) - Inflarx NV  IF0G.DE :
    * INFLARX ANNOUNCES INITIATION OF PHASE III PART OF PHASE
II/III
CLINICAL TRIAL WITH IFX-1 IN SEVERE COVID-19 INDUCED PNEUMONIA
    * INFLARX NV - GERMAN REGULATORY AUTHORITY,
PAUL-EHRLICH-INSTITUT
(PEI), HAS APPROVED PHASE III CLINICAL TRIAL IN GERMANY
    * INFLARX NV - PHASE III PART OF PHASE II/III TRIAL PLANS TO
ENROLL ABOUT 360 EARLY INTUBATED, CRITICALLY ILL PATIENTS WITH
COVID-19 INDUCED PNEUMONIA

Source text for Eikon:  ID:nGNX14fmLH 
Further company coverage:  IF0G.DE 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.